NeoGenomics, Inc. filing amends a prior Schedule 13G to report that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each disclose shared voting and shared dispositive power over 2,222,757 shares of NeoGenomics common stock, representing 1.7% of the class. The filing is accompanied by a Joint Filing Agreement dated May 12, 2026 and clarifies that the shares are held by entities over which the filing parties have voting or investment discretion.
Positive
None.
Negative
None.
Insights
Passive ownership disclosure of a sub‑5% group holding is routine and non‑controlling.
The filing reports shared voting and dispositive power for 2,222,757 shares (stated as 1.7%) held by entities tied to Millennium and Mr. Englander. The joint filing agreement documents coordinated reporting, not an acquisition event.
Implications are limited: this level of ownership is below 5% and the disclosure primarily updates public ownership records; subsequent filings would show material change if the position grows above regulatory thresholds.
Reported position size is modest and unlikely to affect NeoGenomics' capital structure.
The group discloses shared control of 2,222,757 shares, with the filing explicitly describing these as held by entities subject to Millennium's voting or investment discretion. The filing does not state purchases, sales, or timing of transactions.
Market impact is typically minimal for sub‑5% passive holdings; any investor implications would depend on future transactional disclosures that are not present here.
Key Figures
Shared voting power:2,222,757 sharesShared dispositive power:2,222,757 sharesPercent of class:1.7%+2 more
5 metrics
Shared voting power2,222,757 sharesreported on Schedule 13G/A
Shared dispositive power2,222,757 sharesreported on Schedule 13G/A
Percent of class1.7%percent of NeoGenomics common stock reported on cover pages
Joint Filing Agreement dateMay 12, 2026Exhibit I to the Schedule 13G/A
"Amendment No. 1 and cover pages showing beneficial ownership reporting"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedregulatory
"Amount beneficially owned: See response to Item 9 on each cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerfinancial
"Shared Dispositive Power 2,222,757.00 on each cover page"
Joint Filing Agreementlegal
"Exhibit I: Joint Filing Agreement, dated as of May 12, 2026"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
NeoGenomics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
64049M209
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
64049M209
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,222,757.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,222,757.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,222,757.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
64049M209
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,222,757.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,222,757.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,222,757.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
64049M209
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,222,757.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,222,757.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,222,757.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.7 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
NeoGenomics, Inc.
(b)
Address of issuer's principal executive offices:
9490 NeoGenomics Way, Fort Myers, FLORIDA, 33912.
Item 2.
(a)
Name of person filing:
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
64049M209
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
(b)
Percent of class:
See response to Item 11 on each cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
05/12/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
05/12/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
05/12/2026
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of May 12, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
What does the NeoGenomics (NEO) Schedule 13G/A disclose?
It discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 2,222,757 shares, equal to 1.7% of NeoGenomics' common stock, via entities under their discretion.
Does the filing indicate an acquisition or sale of NeoGenomics shares?
No. The Schedule 13G/A updates beneficial ownership reporting and includes a Joint Filing Agreement dated May 12, 2026. It does not state any purchase or sale transactions or timing of trades.
Who holds the shares reported in the Schedule 13G/A for NEO?
The shares are held by entities whose voting and investment discretion is attributed to Millennium Management LLC and affiliated managers; the filing states these entities hold the disclosed 2,222,757 shares under that discretion.
Does 1.7% ownership create control or reporting obligations?
A 1.7% position is below the 5% passive threshold that typically triggers other forms of Section 13 reporting treatment; the filing here is an amended Schedule 13G reflecting current ownership and a joint filing agreement.
